Last reviewed · How we verify
NE-58095 IR
At a glance
| Generic name | NE-58095 IR |
|---|---|
| Sponsor | Takeda |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administration of NE-58095 Tablets (PHASE2, PHASE3)
- Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women (PHASE2)
- Assess the Influence of a High-fat Meal on the Relative Bioavailability Of Two Formulations of Risedronate (PHASE1)
- Food Effects on the Relative Bioavailability of Different Dosages of Risedronate (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NE-58095 IR CI brief — competitive landscape report
- NE-58095 IR updates RSS · CI watch RSS
- Takeda portfolio CI